Determinants of the access to remote specialised services provided by national sarcoma reference centres.
Adolescent
Adult
Aged
Databases, Factual
/ statistics & numerical data
Female
France
Health Services Accessibility
/ organization & administration
Healthcare Disparities
/ organization & administration
Humans
Male
Medical Oncology
/ organization & administration
Middle Aged
Patient Care Team
/ organization & administration
Quality of Health Care
Remote Consultation
/ organization & administration
Sarcoma
/ diagnosis
Young Adult
Cancer care accessibility
Cancer inequalities
Rare cancers
Reference networks
Sarcoma
Spatial inequalities
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 May 2021
29 May 2021
Historique:
received:
10
02
2021
accepted:
19
05
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients. Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery. Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities. In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks' organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.
Sections du résumé
BACKGROUND
BACKGROUND
Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients.
METHODS
METHODS
Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery.
RESULTS
RESULTS
Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities.
CONCLUSIONS
CONCLUSIONS
In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks' organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.
Identifiants
pubmed: 34049529
doi: 10.1186/s12885-021-08393-4
pii: 10.1186/s12885-021-08393-4
pmc: PMC8164290
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
631Références
Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
PLoS One. 2011;6(8):e20294
pubmed: 21826194
J Epidemiol Community Health. 2012 Nov;66(11):982-9
pubmed: 22544918
Eur J Surg Oncol. 2019 Jan;45(1):16-18
pubmed: 29685758
Cancer. 2015 Jan 1;121(1):113-22
pubmed: 25196776
Dis Colon Rectum. 2015 May;58(5):526-32
pubmed: 25850840
Acta Orthop Suppl. 2009 Apr;80(334):1-104
pubmed: 19919379
Cancer Epidemiol. 2016 Aug;43:56-62
pubmed: 27391547
Cancer. 2017 Jul 1;123(13):2516-2523
pubmed: 28241089
BMC Cancer. 2020 Mar 6;20(1):190
pubmed: 32138705
Rural Remote Health. 2008 Oct-Dec;8(4):1003
pubmed: 19012470
Ann Surg. 2016 Feb;263(2):362-8
pubmed: 25563883
Health Place. 2012 Nov;18(6):1412-21
pubmed: 22906754
Health Place. 2014 Nov;30:36-44
pubmed: 25194994
Lung Cancer. 2014 Mar;83(3):401-7
pubmed: 24491311
J Gen Intern Med. 2009 Feb;24(2):205-10
pubmed: 19067086
PLoS One. 2017 Feb 3;12(2):e0158406
pubmed: 28158190
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
Ann Oncol. 2019 Jul 1;30(7):1037-1038
pubmed: 31046083
BMC Cancer. 2012 Aug 13;12:351
pubmed: 22889420
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
ESMO Open. 2020 Feb;5(1):
pubmed: 32079621
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
Am J Epidemiol. 2011 Oct 1;174(7):828-38
pubmed: 21836166
Health Place. 2016 Nov;42:11-18
pubmed: 27614062
Rev Epidemiol Sante Publique. 2019 Feb;67 Suppl 1:S25-S32
pubmed: 30639053
Ann Oncol. 2004 Feb;15(2):307-15
pubmed: 14760127
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Eur J Surg Oncol. 2019 Jan;45(1):1-2
pubmed: 30041942
Int J Health Geogr. 2009 Jul 23;8:48
pubmed: 19627576
Eur J Cancer. 2006 Nov;42(17):3041-8
pubmed: 17029939
Int J Health Geogr. 2020 Nov 9;19(1):46
pubmed: 33298076
PLoS One. 2021 Feb 25;16(2):e0246958
pubmed: 33630918
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Int J Environ Res Public Health. 2018 Oct 10;15(10):
pubmed: 30308955
Eur J Cancer. 2014 Jul;50(11):1951-6
pubmed: 24857344